InnoPharmax Inc.
TWO: 4172.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Weihua Hao
- Employees
- 34
- Headquarters
- Taipei, Taiwan
- IPO year
- 2012
- Market cap
- NT$1.7B
- Website
- https://www.innopharmax.com
Loading 4172…
Loading profile data…Frequently asked questions about 4172
What does InnoPharmax Inc. (4172.TWO) do?
InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company's core products include N11005, a prandial oral insulin; and GemOral. It also offers Imipenem and Cilastatin solution for the treatment of infections caused by susceptible organisms...
Where does 4172.TWO trade?
InnoPharmax Inc. (4172.TWO) trades on the Taipei Exchange.
What sector is 4172.TWO in?
InnoPharmax Inc. (4172.TWO) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of InnoPharmax Inc.?
Weihua Hao is the chief executive officer of InnoPharmax Inc. (4172.TWO).
Where is InnoPharmax Inc. headquartered?
InnoPharmax Inc. is headquartered in Taiwan.
Does 4172.TWO pay a dividend?
InnoPharmax Inc. (4172.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4172.TWO go public?
InnoPharmax Inc. (4172.TWO) completed its initial public offering in 2012.